The results of a study by Sun et al. [9] showed that ezetimibe combined with rosuvastatin was clinically effective in treating early-onset coronary artery disease, effectively reducing serum MCP-1 and MIP-1α expression, regulating blood lipids, and improving cardiac function without increasing adverse effects. The gene discussed is CCL3; the disease is coronary artery disorder.